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ABSTRACT 
Differential expression of microRNAs (miRNAs) has been implicated in leukemogenesis. We investigate the ex-
pression pattern of miR-196b. Using quantitative real-time PCR (qRT-PCR), we detected the expression of miR-
196b and its correlated genes (SMC1A/MLH1) in initial pediatric AML. A significant association was observed 
between overexpression of miR-196b and inferior overall survival of pediatric AML (Log Rank P<0.0001). AML 
M4/5 subtype, high white blood cell (WBC) count at presentation, MLL rearrangement, or FLT3-ITD mutation at 
diagnosis and non-remission group after the first induction chemotherapy possessed higher miR-196b expression. 
Furthermore, a positive relationship was found between the expression of miR-196b and SMC1A/MLH1 (Spear-
man’s r=0.37 and 0.44, P=0.001 and <0.0001, respectively). Taken together, these findings suggest that differen-
tially high expression of miR-196b in diagnostic marrow samples of pediatric AML is associated with unfavorable 
outcome, and miR-196b potentially can be a novel biomarker for the diagnosis, prognosis and treatment in pedi-
atric AML. 
 
Keywords: miR-196b, AML, pediatric/child, biomarker 
 
Abbreviations: qRT-PCR = quantitative real-time reverse transcriptase-polymerase chain reaction, AML = acute 
myeloid leukemia, POMA = Pipeline of Outlier microRNA Analysis, NOD = number of degree, TFP = transcrip-
tion factor percentage, ALL = acute lymphoblastic leukemia, BM = bone marrow, MNCs = mononuclear cells, 
WBC = white blood cell, OS = overall survival 
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INTRODUCTION 
Acute myeloid leukemia (AML) is a 
highly heterogeneous hematopoietic malig-
nancy with increasing identified cytogenetic 
and molecular abnormalities (Valk et al., 
2004). Comparing to adult AML, pediatric 
AML has certain unique biologic properties 
and genetic abnormalities, such as specific 
karyotype (e.g. Trisomy 21), controversial 
role of C-kit mutation, and fewer secondary 
AML, with favorable response to chemother-
apy and significantly different prognosis 
(Creutzig et al., 2012). Over the past few dec-
ades, the five-year survival rate of childhood 
AML improved from around 40 % to 60 %-
75 % (Armendariz et al., 2005; Pui et al., 
2011; Smith et al., 2005; Kaspers and 
Creutzig, 2005), benefiting from risk-strati-
fied therapy (Pui et al., 2011; Li and Xiao, 
2008). Approximately 90 % of AML children 
achieve remission with the combination 
chemotherapy, but relapse (about one third) 
remains the most significant risk in pediatric 
AML (Pui et al., 2011; Creutzig et al., 2012). 
Hence, deeper understanding molecular 
mechanism of AML is desperately needed, 
which can potentially further identify targets 
for effective novel therapies (Moore et al., 
2013). 
MicroRNAs (miRNAs) are small non-
coding RNAs consisting of ~22 nucleotides, 
with highly conserved sequence in vertebrates 
(Lagos-Quintana et al., 2001), which are in-
volved with many cellular processes such as 
proliferation, differentiation, and apoptosis at 
the post-transcription level (Lujambio and 
Lowe, 2012). Also, as described having onco-
genic or anti-oncogenic properties, miRNAs 
are implicated in leukemogenesis and the 
prognosis, due to some microRNA genes lo-
cating in regions of translocations and dele-
tions frequently occurring in leukemia (e.g. 
miR-15a–miR-16-1 cluster and chronic lym-
phocytic leukemia) (Chen, 2005). Moreover, 
miRNA expression profiles could classify 
specific cancers such as discriminating acute 
lymphoblastic leukemia (ALL) from AML 
(Mi et al., 2007). 
In this pilot study, we compared the mi-
croarray expression data of miRNAs and 
mRNAs from pediatric AML, reported from 
the National Center for Biotechnology Infor-
mation comprehensive gene expression data-
base (NCBI GEO database, accession num-
ber: GSE35320 and GSE43176). Based on the 
previous published novel prediction software 
POMA (Pipeline of Outlier microRNA Anal-
ysis) (Zhang et al., 2014), we made further 
improvement to get a specific microRNA-
mRNA network for pediatric AML in order to 
explore relevant biomarkers (Yan et al., 
2015). Through network analysis, miR-196b 
was identified as one of the candidate miRNA 
biomarkers involved in the leukemogenesis of 
childhood AML, due to a significantly larger 
NOD (number of degree) and TFP (transcrip-
tion factor percentage) (Wilcoxon test, 
p<0.05, NOD=30, TFP=0.191) (Zhang et al., 
2014; Yan et al., 2015). Overexpression of 
miR-196b has been reported in 71 European 
pediatric AML with MLL gene rearrange-
ments, NPM1 mutations, as well as FLT3-
ITD in cytogenetically normal background 
(Danen-van Oorschot et al., 2012). To further 
explore and confirm the potential function of 
miR-196b, we investigated the expression of 
miR-196b and its possible relevant genes 
SMC1A/MLH1 in 83 Chinese pediatric 
AML. Quantitative real-time reverse tran-
scriptase-polymerase chain reaction (qRT-
PCR) was performed on bone marrow sam-
ples and cell lines. 
 
METHODS 
Cell culture 
Human myeloid leukemia cell lines, 
HL60, NB4, MV4-11, SHI1, Kasumi-1, and 
K562, were maintained at 37 °C and cultured 
in RPMI-1640 (Hyclone) supplemented with 
10 % fetal bovine serum (FBS) (Bovogen) in 
5 % CO2 humidified atmosphere. SHI-1 cell 
line was cultured in IMDM (Hyclone) supple-
mented with 20 % FBS. 
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Patient samples 
112 bone marrow (BM) specimens from 
83 initial pediatric AML and 29 non-malig-
nancies with age ≤ 18 years were included. 
All specimens were collected randomly be-
fore treatment from January 2012 to October 
2014 in the Affiliated Children’s Hospital of 
Soochow University with informed consent. 
Mononuclear cells (MNCs) were isolated and 
stored at -80 °C prior to RNA extraction. 
AML children were treated according to the 
recommendations for Chinese AML children 
(Subspecialty Group of Hematology Diseases 
et al., 2006). Of 83 AML patients, 63 patients 
were classified as “chemotherapy” group and 
were included in survival analysis, while 20 
patients eventually selected hematopoietic 
stem cell transplantation. Follow-up time 
started from chemotherapy to death or default 
of patients. Twenty-nine BM specimens with 
benign conditions were used as controls, in-
cluding infectious disease (6/29), healthy do-
nor (3/29), and idiopathic thrombocytopenic 
purpura (20/29). The study was approved by 
the ethics committee of the Affiliated Chil-
dren’s Hospital of Soochow University.  
 
Measurement of miR-196b and SMC1A/ 
MLH1 gene expression in clinical samples 
and cell lines 
TaqMan probe based qRT-PCR method 
was applied to detect the expression of miR-
196b and U6 in each bone marrow specimen 
and six cell lines. MiR-196b level was nor-
malized using U6 as a housekeeping gene. All 
small RNA primers and the TaqMan probes 
were designed and supplied by Applied Bio-
systems (ABI) (miR-196b: No. 002215-
PN4427975; U6: No. 001973-PN4427975). 
SMC1A and MLH1 gene were measured on 
mRNA level by SYBGreen based qRT-PCR 
with β-actin as internal control. Primers of 
three mRNAs were designed by Primer Prem-
ier Software (version 5.0) and synthesized by 
Sangon Biotech (Shanghai). The counterpart 
sequences are given in Table 1. 
Table 1: Sequences of genes for SYBGreen 
based qRT-PCR 
Gene Sequence 
SMC1A Sense:  
5'-GTGTCATTGTAGGAGGTTCTT-3' 
Antisense:  
5'-CTTCAGCCTTCACCATTT-3' 
MLH1 Sense:  
5'-TCCCGAAAGGAAATGACT-3' 
Antisense:  
5'-TTGGTGGTGTTGAGAAGGT-3' 
β-actin Sense:  
5'-TTAGTTGCGTTACACCCTTTC-3' 
Antisense:  
5'-GCTGTCACCTTCACCGTTC-3' 
 
 
Total RNA isolation and cDNA synthesis 
Total RNA was extracted using the Trizol 
reagent (Invitrogen, China). RNA quality was 
checked on MULTISKAN GO (Thermo Sci-
entific, China). Reverse transcription (RT) re-
actions were carried out by PCR System 9700 
GeneAmp under each specification. Reaction 
system (15 µl) and parameters of miR-196b 
and U6 were set according to the protocol of 
ABI, while those of SMC1A/MLH1/β-actin 
were set as: 40 μl of sample volume; 70 °C for 
5 min (preheat), then 37 °C for 60 min, 
95 °C for 5 min, and 4 °C forever, for one cy-
cle.  
 
Real-Time Quantitative RT-PCR 
qRT-PCR was executed on ABI 7500 
Real-Time PCR System. MiR-196b and U6 
were detected according to the manufac-
turer’s procedure from ABI. SYBGreen based 
qRT-PCR for SMC1A, MLH1, and reference 
gene β-actin were executed based on the fol-
lowing reaction volume: cDNA 4 μl, 
SYBGreen 1 μl, Mix 12.5 μl, Primer F 0.5 μl, 
Primer R 0.5 μl, and Nuclease-free water 
6.5 μl. Reaction parameters were set as: 50 °C 
2 min, 95 °C 10 min, 95 °C 20 sec, 56 °C 20 
sec, 72 °C 45 sec, 95 °C 15 sec, 60 °C 60 sec, 
95 °C 15 sec, 60 °C 15 sec, 25 μl of reaction 
system, and 40 cycles. Melting curves were 
drawn automatically by computer. 
Triplicates were performed for all qRT-
PCR reactions. Ct threshold was manually set 
at 0.08. Ct value of housekeeping gene U6 
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and β-actin should meet the requirement of 
less than or equal to 25 and 18, respectively. 
The quantitative PCR values of all samples 
were normalized to those of housekeeping 
gene. Using the comparative Ct method, the 
gene relative expressions of 112 samples were 
calculated to median expression in controls 
and expressed in 2-ΔΔCt (Livak and 
Schmittgen, 2001).  
 
Statistical analysis 
All the statistical analyses and plotting 
were performed by SPSS 18.0 and Graphpad 
Prism 5.0 software package. Statistical differ-
ences of genes expression between groups 
were calculated using the Mann-Whitney and 
Kruskal-Wallis test. Spearman’s nonparamet-
ric correlation analysis was used for compari-
son between genes expression and clinical 
features. Kaplan-Meier survival analysis was 
used to assess the impact of gene level on the 
survival time (overall survival, OS). All used 
test were two-sided, P-valueless than 0.05 
was considered as statistically significant. 
 
RESULTS 
Patients’ clinical characteristics, cytoge-
netic and molecular abnormalities were listed 
in Table 2. Based on World Health Organiza-
tion (WHO) classification 2008 (Vardiman et 
al., 2009) and NCCN Guidelines for AML 
(NCCN, 2015), patients were stratified into 
diverse subgroups (Table 3). 
 
Differential expression of miR-196b is  
significantly associated with specific  
subgroups (FAB classification) 
We first tested leukemia cell lines and 
demonstrated significantly higher expression 
of miR-196b in MV4-11/SHI-1 but relatively 
lower in HL60 cell lines, suggesting miR-
196b was not consistently expressed among 
different leukemia lines (Figure 1). In pri-
mary leukemia clinical samples, the level of 
miR-196b was significantly higher in M4/5 
than that in non-M4/5 subgroup with over 62-
fold difference (P<0.0001). Both M4/5 (mon-
ocytic AML series) and non-M4/5 (non-mon-
ocytic AML series) subgroup had statistically 
differential expression compared to those in 
controls (P=0.032, <0.0001, respectively) 
(Table 3, Figure 2A-B). 
 
 
Table 2: FAB (French-America-British) subtypes 
and clinical/cytogenetic/molecular characteristics 
of 83Chinese pediatric AML patients 
Characteristic  
Pediatric AML full 
cohort (n = 83) 
Value (%) 
Age at diagnosis, M  
Median 121 
Range 4.6-216 
Sex, No. (%)  
Male 43 (51.81) 
Female 40 (48.19) 
WBC counts, ×109/L  
Median 24.7 
Range 0.64-459.35 
HB counts, g/L  
Median 80 
Range 39-142 
PLT counts, ×109/L  
Median 30 
Range 10-262 
Peripheral blood blast 
percentage (%)  
 
Median 43 
Range 0-96 
Bone marrow blast 
percentage (%)  
 
Median 69 
Range 21.5-98 
LDH,U/L  
Median 529.05 
Range 111-3910.8 
CRP, mg/L  
Median 13.74 
Range 0.01-201.94 
FAB subtypes, No. (%)  
M1 4 (4.82) 
M2 26 (31.33) 
M3 12 (14.46) 
M4 18 (21.69) 
M5 18 (21.69) 
M6 1 (1.20) 
M7 1 (1.20) 
Not determined 3 (3.61) 
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Table 2 (cont.): 
Characteristic  Pediatric AML full 
cohort (n = 83) 
Value (%) 
Cytogenetic abnormal-
ities, No. (%) 
 
11q23(MLL) 8 (9.64) 
t (8:21) 22 (26.51) 
t (15:17) 11 (13.25) 
inv (16) 9 (10.84) 
CN a 18 (21.69) 
Other b 11 (13.25) 
Not determined 4 (4.82) 
Molecular abnormali-
ties, No. (%) 
 
C-kit 9 (10.84) 
CEBPA 10 (12.05) 
FLT3-ITD 5 (6.02) 
FLT3-TKD 2 (2.41) 
Negative c 35 (42.17) 
Not determined 22 (26.51) 
a CN: cytogenetically normal, without cytogenetic aberrations; 
b Other: Other karyotype, with miscellaneous cytogenetic ab-
errations; c Negative: No positive results were detected 
 
 
Figure 1: Differential expression of miR-196b in 
myeloid leukemia cell lines (HL60, NB4, MV4-11, 
SHI-1, Kasumi-1, and K562). Vertical lines indi-
cate the expression of miR-196b relative to β-ac-
tin in cell lines. Obviously higher levels were found 
in MV4-11 and SHI-1. 
 
 
Overexpression of miR-196b correlated 
with prognostic factors and low remission 
rate after the first induction chemotherapy 
Among abnormal cytogenetic subgroups, 
expression level of miR-196b was the lowest 
in t (8; 21) (n=22) and the highest in MLL-
rearrangement (n=8) compared with other cy-
togenetic subgroups (P=0.0002, P=0.0002, 
respectively). Furthermore, miR-196b ex-
pressions were significantly different among 
various molecular mutation subgroups, with 
the highest expression in FLT3-ITD 
(P=0.04), and the lowest level in C-Kit muta-
tion subgroup (P=0.06) (Table 3, Figure 2C-
D). 
The highest level of miR-196b was found 
in poor prognosis group while the lowest ex-
pression in favorable prognosis group 
(P<0.0001, P<0.0001, respectively). MiR-
196b expression was significantly higher in 
non-remission group (n=15) as compared to 
remission group (n=51) after the first induc-
tion remission therapy (P=0.020). In addition, 
the expression of miR-196b in WBC 
≥ 100×109/L cohort was statistically higher 
compared with WBC<100×109/L cohort 
(P=0.004), and no obvious relationship was 
observed between miR-196b expression and 
blast percentage of PB/BM (P>0.05). Further-
more, statistical difference in miR-196b also 
existed between age ≤ 12 months and > 12 
months subgroups (P=0.029). No signifi-
cantly difference was observed between gen-
ders (P=0.141) (Table 3, Figure 2E-H). 
In summary, miR-196b expression is 
highly correlated with known poor prognostic 
factors in AML, and patients with overex-
pressed miR-196b are not easy to achieve re-
mission. 
 
Correlation analysis of miR-196b levels 
with clinical characteristics and outcome of 
pediatric AML 
Using Spearman’s correlation analysis, 
we compared the relationship of miR-196b 
levels with presenting clinical features, and 
found that miR-196b expression was posi-
tively associated with high WBC, hemoglobin 
(HB), and platelet (PLT) count as well as se-
rum lactate dehydrogenase (LDH) value 
(Spearman’s r=0.27, 0.22, 0.31, 0.23, P=0.01, 
0.04, 0.004, 0.034, respectively) (Figure 3A-
D). No significant correlation between the ex-
pression and serum C-reaction protein (CRP) 
was noted (Spearman’s r=0.22, P=0.052).
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Table 3: Differential expression of miR-196b among diverse clinical/cytogenetic/molecular subgroups 
of AML children. 
Characteristic 
miR-196b 
Case (n) Median  expression (range) a
Fold expression  
vs. rest b P-Value 
c
Cytogenetic abnormalities     
11q23 (MLL) 8 13.75 (4.65-34.32) 101.85 0.0002 
inv (16) 9 0.17 (0.01-6.39) 0.80 0.464 
t (8;21) 22 0.05 (0.01-0.69) 0.08 0.0002 
t (15;17) 11 0.10 (0.001-0.60) 0.42 0.091 
CN d 18 1.49 (0.004-24.50) 14.88 0.285 
Other e 11 8.04 (0.02-114.30) 50.77 0.006 
Molecular abnormalities      
C-kit 9 0.07 (0.01-0.69) 0.32 0.063 
CEBPA 10 0.12 (0.004-0.25) 0.49 0.209 
FLT3-ITD 5 12.88 (0.10-21.01) 109.71 0.037 
FLT3-TKD 2 6.22 1.67 *** 
Negative f 35 0.30 (0.01-65.89) 3.03 0.311 
FAB Subtypes     
M1 4 0.17 (0.01-21.01) 0.74 0.991 
M2 26 0.05 (0.004-24.50) 0.10 0.001 
M3 12 0.09 (0.01-0.60) 0.35 0.044 
M4-5 (Monocyte series group) 36 4.48 (0.01-114.30) 62.27 <0.0001 
NCCN 2013 Prognosis Group     
Favorable prognosis  40 0.09 (0.001-8.04） 0.02 <0.0001 
Intermediate prognosis 29 0.38 (0.01-65.89） 1.69 0.453 
Poor prognosis 14 13.75 (0.10-114.30) 101.85 <0.0001 
One Regimen Response (day 26)     
non-Remission (BM blast ≥ 5 %)  15 8.60 (0.01-34.32) 86.18 0.018 Remission (BM blast < 5 %)  51 0.10 (0.001-24.50) 
Differential expression  
compared to controls     
Entire cohort 83 0.24 (0.001-114.30) 0.24 0.073 
M4-5 36 4.48 (0.01-114.30) 4.48 0.032 
non-M4-5 44 0.07 (0.001-24.50) 0.07 <0.0001 
Controls 29 1 (0.11-3.85) 1 *** 
WBC Subgroups (×109/L)     
≥ 100 14 11.90 (0.01-114.30）
66.42 0.004 
< 100 69 0.18 (0.001-65.89） 
Age Subgroups (Months, M)     
≤ 12 6 6.64 (0.18-114.30) 29.65 0.029 > 12 77 0.22 (0.001-34.32) 
Sex Subgroups     
Male 43 0.21 (0.004-114.30) 0.65 0.141 Female 40 0.32 (0.001-24.50) 
a Median expression relative to normal bone marrow, determined by qRT-PCR; b Median fold expression of specific subgroup 
compared to all other patients; c Determined by Mann–Whitney test, significant P-values (<0.05) in bold italics; d CN: cytogenetically 
normal, without cytogenetic aberrations; e Other: Other karyotype, with miscellaneous cytogenetic aberrations; f Negative: No 
positive results were detected; ***No calculable P-value due to little cases 
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Figure 2: The relative expression of miR-196b determined by qRT-PCR is related to specific FAB 
(French-America-British) classification, cytogenetic/molecular aberrations, and general clinical charac-
teristics in pediatric AML. A: Expression of miR-196b is higher in M4/5 and lower in non-M4/5 subgroup 
as compared to controls. B: Differential miR-196b expression exists in diverse FAB subtypes. C: Differ-
ential expression presents in various cytogenetic subgroups in 79 AML children. D: Expression in rela-
tion to different molecular aberrations detected in 61available patients. E: Overexpression of miR-196b 
is associated with unfavorable outcome. F: Expression of miR-196b is higher in remission group than 
non-remission group. G: Expression of miR-196b is higher in WBC ≥ 100×109/L than in WBC < 
100×109/L cohort. H: Higher expression of miR-196b appeared in age ≤ 12M than age > 12M 
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Figure 3: Correlation analysis of miR-196b expression with primary WBC (A), HB (B), and PLT (C) 
count of peripheral blood (PB) as well as serum LDH value (D) 
 
 
 
To evaluate the association of miR-196b 
level with outcome of AML patient, survival 
analysis was performed for “chemotherapy” 
group (n=63). The median follow-up was 60.4 
weeks, and follow-up rate was 97 %. 63 cases 
were divided into low miR-196b expression 
(≤ median) and high miR-196b expression 
(> median) subgroups. Significant correlation 
was found between low miR-196b expression 
and improved outcome (OS) (Log Rank 
P<0.0001) (Figure 4A). After removing 
twelve cases with M3 subtype, statistical cor-
relation was still observed (Log Rank 
P<0.0001) (Figure 4B). 
 
Overtly differential overexpression in 
SMC1A and MLH1 compared to controls, 
and positive correlation with the expression 
of miR-196b 
SMC1A and MLH1 were studied in 112 
samples. Among them, eighty three were 
newly diagnosed AML. The levels of 
SMC1A/MLH1 were found significantly 
higher as compared to controls (P<0.0001, 
<0.0001, respectively) and positively corre-
late with miR-196b (Spearman’s r=0.37, 
0.44; P=0.001, <0.0001, respectively) (Fig-
ure 5A-D, Table 4). 
We further compared the expression lev-
els of SMC1A/MLH1 among diverse clinical 
subgroups. Statistical difference was also 
found among three prognosis groups 
(P=0.002, 0.025, respectively) (Figure 5E-F).
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Figure 4: Survival analysis performed in chemotherapy group. A: The overall survival rate is statistically 
higher in low miR-196b expression group compared with high miR-196b expression group in 63 cases. 
B: After removing 12 patients with M3 subtype, the overall survival rate in low miR-196b expression 
group is still obviously higher than that in high miR-196b expression group. 
 
Table 4: Correlation analysis between relative expression of miR-196b and clinical characteristics of 
AML children 
miR-196b vs. clinical characteristics Case (n) Spearman's r P-Value* 
miR-196b vs. Age of AML patients 83 -0.14 0.200 
miR-196b vs. WBC count of PB 83 0.27 0.014 
miR-196b vs. HB count of PB 83 0.22 0.049 
miR-196b vs. PLT count of PB  83 0.31 0.004 
miR-196b vs. LDH of PB 82 0.23 0.034 
miR-196b vs. CRP of PB 82 0.22 0.052 
miR-196b vs. Blast percentage of PB 77 -0.03 0.771 
miR-196b vs. Blast percentage of BM 81 0.18 0.105 
miR-196b vs. SMC1A 83 0.37 0.001 
miR-196b vs. MLH1 83 0.44 <0.0001 
*Determined by Spearman’s nonparametric Correlation analysis, significant P-values (<0.05) in bold italic 
 
 
 
However, no obvious correlation was ob-
served between SMC1A/MLH1 expression 
and OS of patients in neither 63 chemother-
apy group (Log Rank P>0.05) nor 51 non-M3 
chemotherapy group (Log Rank P>0.05). 
 
DISCUSSION 
In this exploratory study on the expression 
of miR-196b in newly diagnosed pediatric 
AML in China, we found that miR-196b ex-
pression was significantly higher in M4/5 
(FAB classification) AML, and strongly 
linked to initial high WBC, early treatment re-
sponse, unfavorable chromosome karyotype 
(11q23), and molecular abnormalities (FLT3-
ITD mutation), as well as inferior clinical out-
come (OS). MiR-196b might be a useful prog-
nostic predictor in Chinese pediatric AML. 
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Figure 5: qRT-PCR results for SMC1A/MLH1. The expression of SMC1A/MLH1 is high expression as 
compared to controls, and positively correlates to that of miR-196b. Adverse relevance similar to miR-
196b was also found in prognosis groups, and cytogenetic groups. 
 
 
MiR-196b, which belongs to miR-196 
gene family (miR-196a-1, miR-196a-2, and 
miR-196b), has been reported to inhibit cell 
apoptosis and promote cell proliferation in a 
myeloid leukemia cell line THP-1 (Cao et al., 
2015). In adult AML, higher levels of miR-
196b not only found in MLL-rearranged 
AML (Popovic et al., 2009), but in total pa-
tients compared to healthy donor (Coskun et 
al., 2011). Moreover, the adverse association 
of high miR-196b expression with OS has 
been demonstrated on 53 AML (median age: 
49 years) and 238 adult AML reported in lit-
erature (Wang et al., 2010; Diaz-Beya et al., 
2014). Consistent with these, in the present 
study aimed to pediatric AML, we also found 
similar results for OS related miR-196b level. 
In addition, we showed higher expression of 
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miR-196b in FLT3-ITD mutation, or M4/5 
subtype, which are widely recognized to have 
poor outcomes in clinic. Besides, we also 
found a relatively lower expression of miR-
196b in patients with CEBPA mutation, t (8; 
21) subgroup, which have favorable progno-
sis (Creutzig et al., 2012). Taken together, 
these data directly or indirectly suggested the 
potentially prognostic value of miR-196b. In-
itially differential expression of miR-196b is 
expected to be a novel biomarker for diagno-
sis of specific subtype and prognosis in pedi-
atric AML. 
Nevertheless, certain discrepancies were 
also presented compared with published data. 
Here, the expression of miR-196b on the total 
level was slightly reduced instead of increas-
ing, which is other than previous studies on 
adult AML (Coskun et al., 2011). One of rea-
sons might be that the granulocyte series (M2) 
patients made up the main part of the entire 
cohort (Table 2). We also found a lowest level 
of miR-196b in patient with C-Kit mutation 
compared with others. Earlier studies have 
found that C-Kit mutation is associated with 
unfavorable prognosis of adult AML with t 
(8; 21) ( Boissel et al., 2006), and AML chil-
dren with t (8;21) or CBF-rearrangement 
(Shimada et al., 2006; Manara et al., 2014), 
yet other investigations indicated that no sig-
nificant relevance existed between C-Kit mu-
tation and the prognosis of AML children and 
adults (Pollard et al., 2010; Goemans et al., 
2005; Shih et al., 2008; Riera et al., 2013). As 
is mentioned before, we forcefully demon-
strated the prognostic relevance of low miR-
196b expression to favorable outcome. Thus, 
the results raised the possibility that, C-Kit 
mutation may not necessarily be associated 
with poor outcome in pediatric AML. These 
disputes await more in-depth answers. In ad-
dition, the previous study (Danen-van 
Oorschot et al., 2012) failed to found obvious 
correlation between miR-196b expression 
and OS of pediatric AML as well as to some 
clinical features. It also differs from our re-
sults. We not only showed that the negative 
correlation of miR-196b to OS but also found 
the level elevated with the increasing of initial 
WBC, HB, and PLT count and LDH level of 
PB. Among them, initial WBC count is the 
usual prognostic factor in pediatric AML, yet 
the meanings of HB and PLT are still dismal 
and under-reported. Its clinical significances 
remain to be further investigated. 
To further investigate the potential role of 
miR-196b, we studied SMC1A and MLH1 
genes, which are key genes involved in two 
key pathways related to DNA repair and sta-
bility (i.e. sister chromosome polymerization 
and DNA mismatch repair (MMR) pathway 
respectively), and were reported to contribute 
to the poor outcome of AML. One study from 
Homme et al. (2010) demonstrated the corre-
lation of low SMC1A protein with poor prog-
nosis. The other study from Mao et al. (2008) 
showed that mutated 3’-UTR of MLH1, likely 
by low MLH1 protein level, could cause 
AML relapse. In the present study, we failed 
to meet such results. Instead, we found signif-
icantly higher SMC1A/MLH1 mRNA ex-
pression in poor prognosis group and entire 
AML cohort compared to controls. It seems to 
be different from the previous studies. How-
ever, these two researches on solid tumor 
have demonstrated the overexpression of 
SMC1A mRNA in cervix cancer and human 
glioma (Narayan et al., 2007; Ma et al., 2013), 
which supported our results. Moreover, gene 
expression levels on mRNA level of 
SMC1A/MLH1 were different from that on 
protein level (Homme et al., 2010; Mao et al., 
2008). Furthermore, age might be also an im-
portant factor, which could confer different 
expression profile of SMC1A/MLH1 in chil-
dren. These inconsistencies await deeper in-
terpretation. In addition, we found a robustly 
positive connection between SMC1A/MLH1 
and miR-196b on the mRNA level, under an 
OS correlation with miR-196b but not 
SMC1A/MLH1, which might be due to dif-
ferent detection levels (e.g. mRNA or protein) 
even age-dependent. It also indicated that a 
complex regulatory network could be in-
volved in miR-196b, SMC1A/MLH1, and the 
two pathways as mentioned, which needs fur-
ther investigation. 
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CONCLUSION 
In conclusion, we identified the differen-
tial expression of miR-196b and its clinical 
significance in initial pediatric AML. High 
level of miR-196b is associated with specific 
FAB subtype, cytogenetic and molecular sub-
group, as well as poor outcome. Some limita-
tions can be attributed to individual heteroge-
neity, relatively small sample size, and shorter 
observation duration. Prospective study on 
miR-196b in pediatric AML treatment proto-
col is warranted. 
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